Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

PP405 may encourage earlier hair growth and slightly increase visible hair count but does not reverse hair follicle miniaturization in male pattern baldness. It does not address damage to the dermal papilla or broken Wnt signaling.

The user is frustrated with hair loss, having switched from topical minoxidil and finasteride to dutasteride and oral minoxidil without seeing improvements. They are considering a hair transplant and are advised to continue the current treatment and explore therapy or lifestyle changes.

Apple core extract pills, believed to enhance hair density, are discussed as a potential treatment for hair loss. Users express cautious optimism and interest in trying the product, while acknowledging skepticism and the high cost.

The user is experimenting with a mix of topical treatments, including finasteride and minoxidil, to improve hair growth, particularly at the temples and core. They are also trying various oils, despite skepticism about their effectiveness, to see if they can enhance results without causing harm.

The conversation discusses the failure of Phase 3 trials for the hair loss treatment KX-826, with no significant difference found between the drug and placebo. Some users express disappointment and skepticism, while others discuss alternative treatments like Minoxidil, finasteride, and RU58841.

Hair loss discussion includes Minoxidil, Finasteride, and RU58841 treatments. Pyrilutamide cleared for phase 3 clinical trial in China.

Pyrilutamide did not show effectiveness in regrowing hair compared to a placebo, but it may still help maintain existing hair by preventing DHT from causing follicle miniaturization. Some users believe it could be beneficial when used with other treatments like minoxidil, finasteride, and dutasteride.

Minoxidil's effectiveness varies due to genetic differences in the SULT1A1 enzyme, affecting how well it converts to its active form, minoxidil sulfate. Hyper-responders may experience rapid hair growth and increased side effects, such as pericardial effusion, even at low doses.

Scube3, a potential hair loss treatment, is unlikely to be released because it was given to a startup company, Amplifica, which may go bankrupt and fail to bring the treatment to market. Amplifica is prioritizing other treatments over Scube3, which could lead to financial loss and the end of Scube3's development.

The user is experiencing hair loss despite using finasteride three times a week due to side effects and is considering alternatives like topical finasteride, estrogen blockers, or dutasteride. They are also interested in potential treatments like GT20029 and pyrilutamide.

New hair loss treatments include lab-grown hair cloning, scarless healing with verteporfin, GT20029 for receptor degradation, JAK inhibitors for follicle activation, and dermal papilla stem cell exosomes. These aim to regenerate hair rather than just slow hair loss.

The user experienced significant hair regrowth after three months using a topical combination of minoxidil and dutasteride. They reported no side effects and were surprised by the progress, despite initial skepticism.

Delayed release oral minoxidil is seen as a promising advancement for hair loss treatment, offering safer, higher doses and more consistent hair follicle stimulation compared to current options. However, it is not expected to replace finasteride or dutasteride, as it does not prevent androgenetic alopecia.

Finasteride and minoxidil, often with ketoconazole, are key for long-term hair stabilization and regrowth. Oral minoxidil and dutasteride offer significant regrowth but have more side effects, while microneedling, ketoconazole shampoo, and RU58841 are used to enhance results.

South Korea's president is advocating for hereditary hair loss to be covered by national health insurance due to its impact on mental health and daily functioning. The discussion highlights the societal pressure in South Korea regarding appearance and the potential benefits of treating hair loss to improve mental health.

Clascoterone (Breezula) shows a potential 500% increase in hair growth, possibly outperforming minoxidil and finasteride. It is in advanced trials, with hopes for FDA approval, but cost and side effects are concerns.

Hair mills prioritize volume over care, leading to rushed procedures and potential mistakes like miscalculating graft numbers. It's advised to choose reputable clinics, consider off-season procedures, and ensure doctor involvement for better results.

A user with diffuse thinning recommends a root cover-up spray as a temporary, medication-free solution. They plan to consult a dermatologist for treatments like Minoxidil and finasteride while using the spray for special occasions.

Managing blood pressure can help with hair loss, as seen with the use of medications like Cialis and oral minoxidil, which improved hairline and blood pressure. Lifestyle changes, such as reducing stimulant use and adjusting testosterone replacement therapy (TRT) doses, also play a role in addressing hair loss and overall health.

Celebrities often use brand names like Propecia for finasteride due to brand recognition, marketing, and potential sponsorships. In contrast, the general public and online communities may use generic names, reflecting differences in cultural and healthcare practices.

The conversation discusses the lack of updates on GT20029 for hair loss treatment, with some users noting recent reports indicating ongoing data collection. There are mentions of other treatments like Pyrilutamide and Minoxidil.

The phase 3 trial results for Pyrilutamide showed no significant difference from the control treatment in increasing hair count, leading to the company halting its development. Users discussed their disappointment and skepticism about hair loss treatments, with some mentioning other treatments like Minoxidil, Finasteride, and RU58841.

Hair cloning might be available in 10-15 years, but current and upcoming treatments like finasteride, dutasteride, and new drugs like g20029 may make it unnecessary. Advances in hair regrowth technology and treatments are expected to be more cost-effective and accessible.

After a year of using finasteride, topical minoxidil, Nizoral shampoo, and derma stamping, the user experienced significant hair regrowth and increased hair density, despite an initial shedding phase. The user attributes the success to consistency and patience, noting that derma stamping significantly boosted regrowth speed and quality.

PP405 shows promise in regenerating hair by activating dormant follicles. Other treatments like VDPHL01 and Breezula are also advancing, providing new hope for hair loss solutions.

A 35-year-old shared a 7-day update on their hair transplant, which involved 3,153 grafts performed by Dr. Elif at HLC Ankara, costing 10,000 euros including accommodations. The user has been on finasteride for over 12 years and opted for a partial shave FUE to address hairline recession and temple peaks.

Diffuse thinning is often due to androgenetic alopecia, and DHT blockers like finasteride are recommended. Treatments mentioned include minoxidil, finasteride, dutasteride, and RU58841, with emphasis on starting early and using a holistic approach.

PP405 is a safer alternative to JXL069 for hair loss treatment because it penetrates the skin effectively and degrades in the blood, avoiding systemic toxicity. JXL069, when forced into the body, can cause dangerous side effects like lactic acidosis due to its inability to degrade safely.

Hair loss is linked to scalp fibrosis and tension, which result from chronic mechanical stress and androgenic signaling. Treatments include blocking androgens with finasteride, promoting hair growth with topical minoxidil, and improving scalp mobility through exercises.